SCHEMBL4611220

SCHEMBL4611220

COc1ccc(C(Cl)C#N)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.53
GAA P10253 3/20 0.53
LMNA P02545 2/20 0.49
TSHR P16473 2/20 0.48
MAPK1 P28482 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
PBRM1 Q86U86 1/20 0.45
HTT P42858 1/20 0.43
SLC2A1 P11166 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716539 0.79 ALDH1A1 (0.46) ALDH1A1GAALMNACYP1A2CYP2D6
SCHEMBL27782838 0.79 ALDH1A1 (0.48) ALDH1A1GAATSHRMAPK1TDP1
SCHEMBL5176160 0.78 ALDH1A1 (0.56) ALDH1A1GAALMNATSHRMAPK1
SCHEMBL5054937 0.78 ALDH1A1 (0.60) ALDH1A1GAALMNATSHRMAPK1
SCHEMBL8747263 0.77 AOC3 (0.44) ALDH1A1L3MBTL1CA1CA2CA7
SCHEMBL956691 0.77 ALDH1A1 (0.55) ALDH1A1GAALMNATSHRMAPK1
SCHEMBL8010946 0.76 ALDH1A1 (0.44) ALDH1A1GAALMNATDP1CA1
SCHEMBL9185138 0.75 TSHR (0.54) ALDH1A1GAALMNATSHRMAPK1
SCHEMBL1200448 0.75 TSHR (0.54) ALDH1A1GAALMNATSHRMAPK1
SCHEMBL3960014 0.75 TRPA1 (0.54) ALDH1A1GAALMNATSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1249447-B1 Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol ALEMBIC LTD (IN) 2008-10-22 EP claimed
US-6756502-B2 AS CHEMICAL INTERMEDIATE IN PREPARATION OF VENLAFAXINE ALEMBIC LIMITED (IN) 2004-06-29 US claimed
US-20030195376-A1 Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent ALEMBIC LIMITED (A CORPORATION OF INDIA) (IN) 2003-10-16 US claimed
EP-1249447-A1 Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol Alembic Limited (IN) 2002-10-16 EP claimed
EP-1249447-B1 Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol ALEMBIC LTD (IN) 2008-10-22 EP disclosed
EP-1249447-B1 Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol ALEMBIC LTD (IN) 2008-10-22 EP disclosed
US-20070027156-A1 Crf antagonists and heterobicyclic compounds ONO PHARMACEUTICAL CO., LTD. (JP) 2007-02-01 US disclosed
CN-1878758-A Crf antagonists and heterobicyclic compounds ONO PHARMACEUTICAL CO (JP) 2006-12-13 CN disclosed
EP-1666468-A1 CRF ANTAGONISTS AND HETEROBICYCLIC COMPOUNDS ONO PHARMACEUTICAL CO., LTD. (JP) 2006-06-07 EP disclosed
US-6939888-B2 1-H-3-arylpirrolidine-2,4-dione derivatives BAYER AKTIENGESELLSCHAFT (DE) 2005-09-06 US disclosed
US-6756502-B2 AS CHEMICAL INTERMEDIATE IN PREPARATION OF VENLAFAXINE ALEMBIC LIMITED (IN) 2004-06-29 US disclosed
US-20040019061-A1 1-H-3-arylpirrolidine-2,4-dione derivatives FISCHER REINER (DE) 2004-01-29 US disclosed
US-20030195376-A1 Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent ALEMBIC LIMITED (A CORPORATION OF INDIA) (IN) 2003-10-16 US disclosed
US-6472419-B1 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents BAYER AKTIENGESELLSCHAFT (DE) 2002-10-29 US disclosed
EP-1249447-A1 Intermediate for the production of 1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]-cyclohexanol Alembic Limited (IN) 2002-10-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195376-A1 Novel intermediate and processes for its preparation and conversion into a pharmacologically-active agent CYP3A4, CYP4X1, CYP2F1 ALDH1A1 526/4885GAA 1692/4885LMNA 1089/4885
US-20040019061-A1 1-H-3-arylpirrolidine-2,4-dione derivatives PRXL2A, DDT, CYP4B1 ALDH1A1 792/4885GAA 1674/4885LMNA 2427/4885
US-20070027156-A1 Crf antagonists and heterobicyclic compounds CRHR2, CRHR1, CRH ALDH1A1 3380/4885GAA 4725/4885LMNA 4795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.